Grunt J A, Howard C P, Daughaday W H
Acta Endocrinol (Copenh). 1984 Jun;106(2):168-74. doi: 10.1530/acta.0.1060168.
Somatomedin-C (Sm-C) and growth hormone (GH) levels were determined before, during and after human growth hormone (hGH) treatment in 18 children with small-for-date short stature ( SDSS ), 7 children with significant idiopathic short stature ( SISS ) and 14 children with hypopituitarism. Data on the acute effects of hGH on Sm-C were compared to growth responses after 6 to 9 months therapy. Eleven of the 25 non-hypopituitary patients with normal basal and stimulated serum GH levels and normal basal Sm-C levels increased their rates of growth more than 3.0 cm/year. This compared with 11 of the 14 children with hypopituitarism who increased their rates of growth by at least 3.0 cm/year when treated with GH. Neither the basal somatomedin levels nor the GH-stimulated somatomedin levels correlated well with subsequent growth in the non-hypopituitary patients. These studies indicate that GH therapy may be effective in treating short stature in children without demonstrable GH deficiency.
对18名小于胎龄儿身材矮小（SDSS）儿童、7名显著特发性身材矮小（SISS）儿童和14名垂体功能减退儿童在人生长激素（hGH）治疗前、治疗期间和治疗后测定了生长调节素C（Sm-C）和生长激素（GH）水平。将hGH对Sm-C的急性作用数据与6至9个月治疗后的生长反应进行了比较。25名非垂体功能减退患者中，11名基础和刺激后血清GH水平正常且基础Sm-C水平正常的患者生长速率增加超过3.0厘米/年。相比之下，14名垂体功能减退儿童中，11名在接受GH治疗时生长速率至少增加3.0厘米/年。在非垂体功能减退患者中，基础生长调节素水平和GH刺激后的生长调节素水平均与随后的生长无良好相关性。这些研究表明，GH治疗可能对治疗无明显GH缺乏的儿童身材矮小有效。
